Country: United Kingdom
Language: English
Source: VMD (Veterinary Medicines Directorate)
Oxytetracycline
Eurovet Animal Health B.V.
QJ01A
Oxytetracycline
Solution for injection
POM-V - Prescription Only Medicine – Veterinarian
Cattle, Pigs
Antimicrobial
Authorized
2002-04-24
1 PART IB - 1 SUMMARY OF PRODUCT CHARACTERISTICS CYCLOSOL LA UK/V/0177/001/R/001 EUROVET ANIMAL HEALTH B.V. THE NETHERLANDS 2 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cyclosol LA, 200 mg/ml Solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each millilitre contains: ACTIVE SUBSTANCE Oxytetracycline (as dihydrate) 200.0 mg (Equivalent to 216 mg Oxytetracycline dihydrate) EXCIPIENTS: Sodium formaldehyde sulphoxylate dihydrate (preservative) 5.0 mg Povidone (complexing agent) 50.0 mg For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for Injection A clear yellow to reddish-brown aqueous solution.” 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Cattle and pigs 4.2 INDICATION FOR USE Cattle: For the treatment of respiratory infections caused by oxytetracycline susceptible organisms such as _ Arcanobacterium (Actinomyces) pyogenes_ and _Haemophilus somnus._ Pigs: For the treatment of respiratory infections caused by oxytetracycline susceptible organisms such as _Pasteurella multocida._ 4.3 CONTRAINDICATIONS Hypersensitivity to tetracyclines. The use of oxytetracycline in animals with an impaired liver and/or kidney function should be avoided. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS It is strongly recommended to divide the intramuscular dosages over two or more injection sites 3 (see posology). For the 250 mL pack, the use of a multidose syringe is recommended. To refill the syringe, the use of a draw off needle is recommended to avoid excessive broaching of the stopper. It is recommended to use Cyclosol LA in the early stages of disease and to evaluate the response to treatment within 72 hours. Resistance against oxytetracycline may vary. Use of the product should be based on susceptibility testing and taking into account official and local antimicrobial policies. Inappropriate use of the product may increase the prevalence of bacteria resistant to oxytetracycline and may decrease the effectiven Read the complete document